SlideShare une entreprise Scribd logo
1  sur  93
Dr. Muhabat Salih Saeid
 MRCOG-London-UK
Definition : It is a clinical term used to
 indicate three closely related
 conditions characterized by active
 abnormal proliferation of
 trophoblastic cells : :
hydatidiform mole ,
invasive hydatidiform     mole and
Choriocarcinoma
 These neoplasm's retain
 certain characteristic of the
 normal placenta such as
 invasive tendencies and the
 ability to make hCG
 hormone
 Pathological classification :
 Hydatidiform mole = 80 % of cases.
 Invasive mole =12-15% of cases.
 Choriocarcenoma=5-8% of cases.
 Clinical classification : The course, and prognosis
  of the disease accurately reflected by hCG
  hormone
 Benign = 80%
 Malignant=20%
 The hydatidiform mole incidence ranges from 1
  in 522 pregnancies in Japan
 To 1 in 1500 pregnancies in USA,and Sweden, this
  variation is not understood, but ethnic factors
  have been suggested .
 The incidence is higher in the poorest
  socioeconomic classes than the semiprivate(4
  times), and (8 times) than the privet , and these
  mostly related to diet especially protein deficiency
  .
 The maternal age over 40 years
 found to have a 5.2-fold increased
 risk of trophoblastic disease in
 compression to the mothers below
 the age of 35 years.
 Hydatidiform mole can be
 subdivided into:
complete and
partial mole
 Based on:
1.Genetic    and
2.Histopathological
features
   Genetic features: One of the most remarkable
  discoveries about hydatidiform mole has been the
  demonstration that complete moles have
  chromosomes exclusively from the paternal side
  ,and the karyotype is nearly always 46,xx and
  only rarely is 46,XY observed.
 The normal mechanism is for a haploid
  sperm,23X,to fertilize an empty egg, and to
  duplicate itself to form a 46,XX complement.
  Much less commonly ,two spermatozoa, one being
  23,X, and the other,23,Y, can fertilize an empty
  egg, to give karyotype a 46,XY.
•10
Aretriploid in origin
with two sets of
paternal haploid genes
and one set of maternal
haploid genes
•12
 They   occur, in almost all
  cases, following dispermic
  fertilization of an ovum.
 There is usually evidence of
  a fetus or fetal red blood cells
   In the partial moles ,the normal
    finding is a triploid karyotype ,69
    chromosomes instead of normal 46.
    The most common mechanism appears
    to be fertilization of normal egg by two
    sperm, giving a complement of
    69,XXY.
Complete mole :
 there are numerous   edematous
 vesicles, which looks like a bunch
 of small clear grapes,
 usually no fetus, or membranes.,
      microscopically: there are:
    large oedematous enlarged villi ,
   a vascular ,
   with variable degree of trophoblastic hyperplasia.
   carries greater risk of malignancy and requires
    longer follow up than the partial mole.
•Partial mole




•Complete mole


                                 •17
•Partial mole




•Complete mole



                                 •18
   Partial mole:
 Shows  a less clear -cut picture ,with
  the formation of vesicles usually focal ,
 fetus and membranes may present,
 the vesicles have degree of vascularity.
 In general ,the more active
  trophoblastic appearance the
  greater the risk of malignancy.
 So the subsequent management
  depends more on the hCG results
  than the histological reports.
Bleeding   : Bleeding in early
 pregnancy after variable period of
 amenorrhea is the most common
 clinical sign of the mole (occurs in
 90% of cases), with the passage of
 the vesicles.
Hyperemesis    gravidarum :
 Occurs into 25% of cases of
 moles ,and appears more
 common when the uterus is
 much enlarged and hCG levels
 are very high.
 Uterine  enlargement: The uterus is
  commonly “large for date”in 50% of case of
  moles ,
 although, in a small proportion of cases the
  uterus corresponding to the gestational age
  or smaller than date.
 The uterus having a doughy consistency.
 The fetal parts are not palpable, and fetal
  heart is absent.
Large  theca lutein cysts of the
 ovary are present in “20%”of
 moles , these may be
 exaggerated the clinical picture
 of large for date uterus. These
 cysts are manifestation of
 excessive hCG.
•25
   Pre-eclampsia :Occur in association
    with the moles with range widely from
    12-54%,these due to differing times of
    diagnosis, the longer pregnancy
    progresses ,the greater chance to
    developing pre-eclampsia. If the signs
    of pre-eclampsia appears early in
    pregnancy , the possibility of
    hydatidiform mole should be looked
    for with out delay.
 Hyperthyrodism: Develop    in small
 proportion of women ,and this may be due
 to thyrotrophic effects of the human
 chorionic thyrotrophin , which may lead to
 goitre,fine tremor ,supra-ventricular
 tachycardia, and weight loss.
 DIC can develop in long-standing hydatidiform
 moles , when there is embolization of
 trophoblastic tissue to the lung, leads to
 thromboplastic substances which stimulate
 fibrin,and platelet deposition.
History and examination :
 From the history of
 amenorrhea ,passage of vesicles
 vaginally with bleeding ;the size
 and consistency of the uterus.
The increasing use of
ultrasound in early
pregnancy has probably
led to the earlier
diagnosis of molar
pregnancy
By the U/S examination can
be diagnosed from very early
pregnancy ,characterized by
“Snow-storm" appearance.
•31
By very high levels of serum
hCG than the normal singleton
pregnancy ,which is diagnostic
and prognostic to the course of
the disease ,with very short
dappling time.
The risks of hydatidiform mole are:
 Immediate hemorrhage ,sepsis, or pre-
  eclampsia; the treatment of these
  conditions has vastly improved
  recently.
 Molar metastases :
  Of a non proliferative ”benign” type
  can occur.
   Choriocarcinoma: The most important
    danger association with the
    hydatidiform mole is the development
    of malignant GTD(Invasive mole or
    choriocarcinoma) in about 10% of
    cases,
The aim of treatment is to eliminate
 all trophoblastic tissue from the
 maternal systems ;
 If the hydatidiform mole diagnosed
 ,steps should be taken to evacuate
 the uterus, and this achieved by:
Suction & curettage
(S&C): The method of
choice even when
evacuation large mole
   Under GA.
   Cervix dilation till 12mm.and S&C induced
    to the uterine cavity.
   I.V oxytocin infusion is started .
   S&C started by negative pressure of about
    60 to 70cmHg.
   The curette is genteelly rotated to ovoid
    perforation of the soft uterus, and the
    majority of the molar tissue is evacuated
    rapidly ,and the uterine size decreases
Uterine   stimulation.
Medical termination of complete
 molar pregnancies including
 cervical preparation prior to
 suction evacuation, should be
 avoided where possible.
 The contraction of the myometrium
  may force tissue into the venous spaces
  at the site of the placental bed.
 The dissemination of this tissue may
  lead to the profound deterioration in
  the woman, with embolic and
  metastases disease occurring in the
  lung
Surgical   evacuation:
   Surgical evacuation: Hysterectomy has been
    recommended as a suitable method of
    treating hydatidiform mole in older women
    who completed their family ,to reduce the
    risk of post-molar trophoblastic disease .
    .The hysterectomy should be carried out
    with little monopolization to ovoid
    precipitating mobilization of trophoblastic
    tissue.
 Inpartial molar pregnancies
 where the size of the fetal
 parts deters the use of
 suction curettage, medical
 termination can be used.
   After the uterus has been evacuated :
 About  90% of cases ,the trophoblastic tissue
  die out completely.
 About 10% of cases the trophoblastic tissue
  does not die out completely and may persist
  or recur as : invasive mole or
  choriocarcinoma.
So it is important that women who
 have had a hydatidiform mole:
 should have close follow-up by serum
 hCG levels after the evacuation of the
 uterus,
To ensure early recognition of persistent
 trophoblastic tissue .
 After a molar pregnancy ,the hCG
  levels will usually have returned to non
  pregnant levels by 4 to 6 weeks after
  evacuation.
 The follow-up is recommended for 2
  years in cases of complete moles, and 6
  months of cases of partial moles after
  the evacuation of uterus.
 Serial quantitative measurement of
 serum hCG level at weekly
 intervals, after evacuation of moles
 till 4 to 5 weeks when the hCG
 become normal. Then every other
 week .When the titer gets negative
 the measurements are done every
 month fore 1 year.
 Indicationof chemotherapy after
 the evacuation of the hydatidiform
 mole in:
Serum hCG >20000 i.u/L , at any
 time after evacuation of mole.
 Raised hCG at 4 to 6 weeks after
 evacuation of mole.
Evidence  of metastases
 ,hepatic,brain,and pulmonary.
Persistent uterine hemorrhage
 after evacuation of mole with
 raised hCG levels.
   To achieve effective follow-up ,the
    pregnancy is better to be avoided ,and also
    the use of oral contraceptive pills until the
    hCG levels returns to normal after the
    evacuation of the mole.
   Early diagnosis of persistent trophoblastic
    disease ensures a good prognosis and an
    effective system of follow-up.
Malignant trophoblastic disease can
 exist in two forms:
Invasive mole = non-metastatic form.
Choriocarcinoma = metastatic form .
 Both treated with the chemotherapy
  and monitored by hCG tumor marker.
 Choriocarcinoma subdivide into :
 good-prognosis (Low-risk) ,and
 poor- prognosis (High-risk).
 The diagnosis of invasive moles or
  “chorioadenoma destruens” is applied to
  the moles characterized by :
 Abnormal peneterativeness and,
 Extensive local invasion, along with
 Excessive trophoblastic proliferation ,
 With preserved villous pattern.
    The proliferative villi may invade the
    myomatrum ,paramatrum or the vaginal
    wall, although there is rarely evidence of
    metastasis.
   The morbidity and mortality of this disease
    results from the penetration of the tumar
    through the myomatrum and to the pelvic
    vessels with the resultant hemorrhage “the
    morbidity and mortality rate 10 %” .
 Choriocarcinoma subdivide
 into:
good-prognosis (low risk).
Poor- Prognosis (High risk).
•56
 The  incidence of choriocarcinoma
  in the West: 1 :10000 and 1:70000
  pregnancies; and
 In Asia between 1:250 and 1:6000
  pregnancies..
 The antecedent pregnancy is :
Hydatidiform mole in about 57%
 of cases.
Normal pregnancy in about 26%
 of cases.
Abortion and ectopic pregnancy in
 about 17% of cases.
 The risk of Choriocarcinoma
 after a hydatidiform mole is
 about 2-4% which is 1000 times
 greater than after a normal
 pregnancy.
 Choriocarcinoma     is more
  likely to occur after complete
  mole .
 The incidence is in excess in
  maternal blood group A, and
  deficit in group O.
 Site: In the uterus 90% of
 cases; 10 % of cases in the
 ovaries ,vagina, vulva, lung,
 liver, and brain.
 Macroscopically:
 Uterus: It may be localized in the form
 of hemorrhagic polyp or multiple
 hemorrhagic ,necrotic masses in the
 cavity.
 Some times it is present in the uterine
 wall (intramural) and the cavity is
 empty.
Ovaries : May show stormal lutein
 hyperplasia, and theca-lutein cysts.
 And may be site of secondaries.
 Microscopically:
 Malignant hyperplasia of both
  cytotrophoblasts,and syncytiotrophoblasts.
 Extensive hemorrhage.
 Absence of villi.
 Destruction of the surrounding
  myomatrum.
   Direct : Through the myomatrum and
    may end in uterine perforation
    ,internal hemorrhage, and peritonitis
    .Through the fallopian tubes to the
    ovaries.
•66
 Blood : The main method of spread ,and
  occurs to;
 Genital : Vagina, vulva, and ovary.
 Extra genital : Lung, liver, brain, and
  bones especially skull and spine.
 The lung is the commonest site for
  secondaries and haemoptysis may be the
  presenting symptom.
 Lung
 Vagina
 Brain
 Liver




           •68
 Vaginal bleeding.
 Haemoptysis.
 Intraperitoneal hemorrhage.
 Peritonitis.
 Metastasis to the vital organs
  e.g,brain.
 Pulmonary complications.
 Symptoms :
 Recent history of expulsion of vesicular
  mole ,or abortion, or full term pregnancy.
 Persistent vaginal bleeding is the
  commonest presentation.
 Haemoptysis.
 Abdominal swelling (uterus or ovaries).
 PersistentGTD should be
 considered in any woman
 developing:
 acute respiratory or
 neurological symptoms
 after any pregnancy.
 Signs:
 Marked deterioration of the
 general condition.
 An abdominal swelling may be
 felt.
 Vaginally :
The uterus  symmetrically enlarged
 (less than 12 weeks).
The ovaries may be enlarged.
Hemorrhagic secondaries may be
 seen in the vagina or vulva
 Investigation:
 Serum hCG.
 Chest X-ray for pulmonary metastasis.
 L.F.T .
 Liver scan.
 CAT scan for the secondaries.
 EEG .
 U/S for abdomen and pelvis.
 Diagnostic D&C.
The clinical classification of gestational
   trophoblastic disease:
I.    Non-metastatic.
II.   Metastatic:
A.    Low risk: All patient of documented
      metastatic disease who do not have “high-
      risk factors”.
B. High risk:
1. B-hCG level higher than
   100.000miu/ml.
2. Associated pregnancy episode
   more than 4 months before the
   diagnosis.
3.   Following full-term pregnancy.
4.   Liver or brain metastasis.
5.   Failure of previous chemotherapy.
6.   Symptoms of malignancy more than 4
     months
    Prophylaxis: After care of vesicular
     mole;
    D&C after one week of the
     evacuation.
    Monitored for the signs and symptoms of
     trophoblastic neoplassmic by:.
I.   serial hCG.
II.   Diagnostic D&C is done if :
     The hCG levels remains high.
     The hCG levels rises after gets negative.
     Uterine sub involution.
     Persistence of theca lutein cysts in the ovaries.
     Every case of secondary postpartum
      haemorrhage.
     Every case of post abortive bleeding.
I.   Non metastatic GTD:
o    Methotrexate (antimetabolite) +folinic
     acid.
o    The cytotoxic therapy is controlled by
     doing CBC,platelet count and LFT.
o    After the the hCG level gets normal ;stop
     the therapy and follow-up by weekly
     estimation of hCG levels.
   Women scoring: Non metastatic
    GTD,and(low risk) GTD receive
    intramuscular methotrexate on alternate
    days, followed by six rest days, with each
    course consisting of four injections
o   Physical examination, chest x-
    ray, and LFT.
o   Total abdominal hysterectomy ,if the
    patient does not desire to maintain
    child-bearing, in the middle of the
    first treatment course .
II.   Low metastatic GTD:
o     Methotraxate , or Actinomycin D
      ,if there is resistance ,change to
      triple chemotherapy.
o   The criteria for initiation, and
    continuation of each methotraxate
    treatment ;
   Platelet count more than 100.000.
   WBC more than 3000.
   Absolute neutrophil count between 1000-
    1500.
   Normal LFT, renal function.
III.   High risk metastatic GTD :
o      Triple chemotherapy :
       Methotraxate, Actinomycin D,
       and Cytoxan.
o Surgery:
 TAH may    be done in patients not
  desirous of further reproduction.
 Surgical extirpation of isolated
  metastasis e.g. pulmonary if
  resistant to chemotherapy.
o Irradiation: Whole brain
 irradiation for cerebral
 metastases , The whole organ
 irradiation for hepatic
 metastases
 After successful therapy ,the hCG
  levels are obtained :
 every 2weeks for 3 months,
 every month for 3months,
 every 2months for 6 months then every
  sixes months indefinitely.
 If at any time hCG levels rises, repeat
  the evaluation , staging ,and
  chemotherapy.
 Physical examination, and chest x-ray
  follow-up at 6 weeks, then every
  3months for one year, then every 6
  months for one year.
 Pregnancy is not allowed except after
  one year of negative follow up but with
  danger of :
 Molar pregnancy (4-5 times greater
  risk).
 Spontaneous abortion.
 Premature delivery.
If a further molar
 pregnancy does occur,
 in 68–80% of cases
 it will be of the
 same histological type
 Women  who undergo
chemotherapy are advised
not to concieve for one year
after completion of
treatment
THIS IS THE END OF THE
 LECTURE .
  HOPE YOU ENJOYED IT !


     THANK YOU ! ! !

Contenu connexe

Tendances (20)

Pelvic inflammatory disease (pid)
Pelvic inflammatory disease (pid)Pelvic inflammatory disease (pid)
Pelvic inflammatory disease (pid)
 
VACCINATIONS IN PREGNANCY BY DR SHASHWAT JANI
VACCINATIONS IN PREGNANCY BY DR SHASHWAT JANIVACCINATIONS IN PREGNANCY BY DR SHASHWAT JANI
VACCINATIONS IN PREGNANCY BY DR SHASHWAT JANI
 
Vulval ca and vulval lymph
Vulval ca and vulval lymphVulval ca and vulval lymph
Vulval ca and vulval lymph
 
Chorioamnionitis Dr Simon Byonanuwe
Chorioamnionitis Dr Simon ByonanuweChorioamnionitis Dr Simon Byonanuwe
Chorioamnionitis Dr Simon Byonanuwe
 
FEVER IN PREGNANCY BY DR SHASHWAT JANI
FEVER IN PREGNANCY BY DR SHASHWAT JANIFEVER IN PREGNANCY BY DR SHASHWAT JANI
FEVER IN PREGNANCY BY DR SHASHWAT JANI
 
Gtn 1 ppt
Gtn 1 pptGtn 1 ppt
Gtn 1 ppt
 
Management-of-Postterm-Pregnancy
Management-of-Postterm-PregnancyManagement-of-Postterm-Pregnancy
Management-of-Postterm-Pregnancy
 
Tubo ovarian absess
Tubo ovarian absessTubo ovarian absess
Tubo ovarian absess
 
Retained placenta
Retained placentaRetained placenta
Retained placenta
 
Clinical Features & Diagnosis of Maternal Sepsis
Clinical Features & Diagnosis of Maternal SepsisClinical Features & Diagnosis of Maternal Sepsis
Clinical Features & Diagnosis of Maternal Sepsis
 
Abortion and post abortion care
Abortion and post abortion careAbortion and post abortion care
Abortion and post abortion care
 
Prom and pprom
Prom and ppromProm and pprom
Prom and pprom
 
Placenta praevia: A brief overview
Placenta praevia: A brief overviewPlacenta praevia: A brief overview
Placenta praevia: A brief overview
 
Preeclampsia
PreeclampsiaPreeclampsia
Preeclampsia
 
Laparoscopic Sterilization
Laparoscopic SterilizationLaparoscopic Sterilization
Laparoscopic Sterilization
 
myomectomy
myomectomymyomectomy
myomectomy
 
Cholestasis of pregnancy
Cholestasis of pregnancyCholestasis of pregnancy
Cholestasis of pregnancy
 
Ectopic Pregnancy
Ectopic PregnancyEctopic Pregnancy
Ectopic Pregnancy
 
Molar pregnancy
Molar pregnancyMolar pregnancy
Molar pregnancy
 
Ectopic pregnancy
Ectopic pregnancy Ectopic pregnancy
Ectopic pregnancy
 

En vedette

medicine.Poisoningbyspecificdrugs.(dr.shaikhani)
medicine.Poisoningbyspecificdrugs.(dr.shaikhani)medicine.Poisoningbyspecificdrugs.(dr.shaikhani)
medicine.Poisoningbyspecificdrugs.(dr.shaikhani)student
 
anaestheisa
anaestheisaanaestheisa
anaestheisastudent
 
meidicine. first seizure.(dr.muhamad tahir)
meidicine. first seizure.(dr.muhamad tahir)meidicine. first seizure.(dr.muhamad tahir)
meidicine. first seizure.(dr.muhamad tahir)student
 
Immunization2
Immunization2Immunization2
Immunization2student
 
Assessment examination1
Assessment examination1Assessment examination1
Assessment examination1student
 
بسم الله الرحمن الرحيمAph
بسم الله الرحمن الرحيمAphبسم الله الرحمن الرحيمAph
بسم الله الرحمن الرحيمAphstudent
 
medicine.Coma managment.(dr.muhamad tahir)
medicine.Coma managment.(dr.muhamad tahir)medicine.Coma managment.(dr.muhamad tahir)
medicine.Coma managment.(dr.muhamad tahir)student
 
medicine.CRF2.(dr.kawa)
medicine.CRF2.(dr.kawa)medicine.CRF2.(dr.kawa)
medicine.CRF2.(dr.kawa)student
 
medicine.Vasculitis 2.(dr.kawa)
medicine.Vasculitis 2.(dr.kawa)medicine.Vasculitis 2.(dr.kawa)
medicine.Vasculitis 2.(dr.kawa)student
 
Catch up vaccine
Catch up vaccineCatch up vaccine
Catch up vaccinestudent
 
medicine.Age and aging lecture 1.(dr.aso)
medicine.Age and aging lecture 1.(dr.aso)medicine.Age and aging lecture 1.(dr.aso)
medicine.Age and aging lecture 1.(dr.aso)student
 
Atlas of opthalmology_tanta_university
Atlas of opthalmology_tanta_universityAtlas of opthalmology_tanta_university
Atlas of opthalmology_tanta_universityDrAfiqahMF
 
Gestational trophoblastic disease
Gestational trophoblastic diseaseGestational trophoblastic disease
Gestational trophoblastic diseaseMuni Venkatesh
 
Electrocardiographymain
ElectrocardiographymainElectrocardiographymain
Electrocardiographymainstudent
 
Gyne,obst slides
Gyne,obst slidesGyne,obst slides
Gyne,obst slidesstudent
 
Development
DevelopmentDevelopment
Developmentstudent
 
Ectopic pregnancy
Ectopic pregnancyEctopic pregnancy
Ectopic pregnancystudent
 
Disfunctional uterine bleeding.gynaecology
Disfunctional uterine bleeding.gynaecologyDisfunctional uterine bleeding.gynaecology
Disfunctional uterine bleeding.gynaecologystudent
 
Anatomy and physiology of the eye
Anatomy and physiology of the eyeAnatomy and physiology of the eye
Anatomy and physiology of the eyeBahaa Halwany
 

En vedette (19)

medicine.Poisoningbyspecificdrugs.(dr.shaikhani)
medicine.Poisoningbyspecificdrugs.(dr.shaikhani)medicine.Poisoningbyspecificdrugs.(dr.shaikhani)
medicine.Poisoningbyspecificdrugs.(dr.shaikhani)
 
anaestheisa
anaestheisaanaestheisa
anaestheisa
 
meidicine. first seizure.(dr.muhamad tahir)
meidicine. first seizure.(dr.muhamad tahir)meidicine. first seizure.(dr.muhamad tahir)
meidicine. first seizure.(dr.muhamad tahir)
 
Immunization2
Immunization2Immunization2
Immunization2
 
Assessment examination1
Assessment examination1Assessment examination1
Assessment examination1
 
بسم الله الرحمن الرحيمAph
بسم الله الرحمن الرحيمAphبسم الله الرحمن الرحيمAph
بسم الله الرحمن الرحيمAph
 
medicine.Coma managment.(dr.muhamad tahir)
medicine.Coma managment.(dr.muhamad tahir)medicine.Coma managment.(dr.muhamad tahir)
medicine.Coma managment.(dr.muhamad tahir)
 
medicine.CRF2.(dr.kawa)
medicine.CRF2.(dr.kawa)medicine.CRF2.(dr.kawa)
medicine.CRF2.(dr.kawa)
 
medicine.Vasculitis 2.(dr.kawa)
medicine.Vasculitis 2.(dr.kawa)medicine.Vasculitis 2.(dr.kawa)
medicine.Vasculitis 2.(dr.kawa)
 
Catch up vaccine
Catch up vaccineCatch up vaccine
Catch up vaccine
 
medicine.Age and aging lecture 1.(dr.aso)
medicine.Age and aging lecture 1.(dr.aso)medicine.Age and aging lecture 1.(dr.aso)
medicine.Age and aging lecture 1.(dr.aso)
 
Atlas of opthalmology_tanta_university
Atlas of opthalmology_tanta_universityAtlas of opthalmology_tanta_university
Atlas of opthalmology_tanta_university
 
Gestational trophoblastic disease
Gestational trophoblastic diseaseGestational trophoblastic disease
Gestational trophoblastic disease
 
Electrocardiographymain
ElectrocardiographymainElectrocardiographymain
Electrocardiographymain
 
Gyne,obst slides
Gyne,obst slidesGyne,obst slides
Gyne,obst slides
 
Development
DevelopmentDevelopment
Development
 
Ectopic pregnancy
Ectopic pregnancyEctopic pregnancy
Ectopic pregnancy
 
Disfunctional uterine bleeding.gynaecology
Disfunctional uterine bleeding.gynaecologyDisfunctional uterine bleeding.gynaecology
Disfunctional uterine bleeding.gynaecology
 
Anatomy and physiology of the eye
Anatomy and physiology of the eyeAnatomy and physiology of the eye
Anatomy and physiology of the eye
 

Similaire à Gestational trophoblastic disease 2

Seminar on gestational trophoblastic disease (gtd) (f inal)
Seminar on gestational trophoblastic disease (gtd) (f inal)Seminar on gestational trophoblastic disease (gtd) (f inal)
Seminar on gestational trophoblastic disease (gtd) (f inal)Santosh Narayankar
 
Gestational trophoblastic disease (gtd.version gao)
Gestational trophoblastic disease (gtd.version gao)Gestational trophoblastic disease (gtd.version gao)
Gestational trophoblastic disease (gtd.version gao)Ayub Medical College
 
choriocarcinoma ppt.pptx
choriocarcinoma ppt.pptxchoriocarcinoma ppt.pptx
choriocarcinoma ppt.pptxPoonamJhamb3
 
Gynecology 5th year, 5th & 6th lectures (Dr. Muhabat Salih Saeid)
Gynecology 5th year, 5th & 6th lectures (Dr. Muhabat Salih Saeid)Gynecology 5th year, 5th & 6th lectures (Dr. Muhabat Salih Saeid)
Gynecology 5th year, 5th & 6th lectures (Dr. Muhabat Salih Saeid)College of Medicine, Sulaymaniyah
 
Gestational Trophoblastic Disease - www.jinekolojivegebelik.com
Gestational Trophoblastic Disease - www.jinekolojivegebelik.comGestational Trophoblastic Disease - www.jinekolojivegebelik.com
Gestational Trophoblastic Disease - www.jinekolojivegebelik.comjinekolojivegebelik.com
 
Gestational trophoblastic disease
Gestational trophoblastic diseaseGestational trophoblastic disease
Gestational trophoblastic diseasepriya saxena
 
GESTATIONAL TROPHOBLASTIC DISEASE...pptx
GESTATIONAL TROPHOBLASTIC DISEASE...pptxGESTATIONAL TROPHOBLASTIC DISEASE...pptx
GESTATIONAL TROPHOBLASTIC DISEASE...pptxIram Chaudhry
 
Gestational trophoblastic disease natangwe
Gestational trophoblastic disease natangweGestational trophoblastic disease natangwe
Gestational trophoblastic disease natangweNatangwe Tangi
 
Gestational Trophoblastic Disease -MBChB 6th Year 2018.pptx
Gestational Trophoblastic Disease -MBChB 6th Year 2018.pptxGestational Trophoblastic Disease -MBChB 6th Year 2018.pptx
Gestational Trophoblastic Disease -MBChB 6th Year 2018.pptxRobertoMaina2
 
Gestational Trophoblastic Disease.ppt
Gestational Trophoblastic Disease.pptGestational Trophoblastic Disease.ppt
Gestational Trophoblastic Disease.pptMohammadTalha294621
 
Gestational Trophoblastic Disease
 Gestational Trophoblastic Disease  Gestational Trophoblastic Disease
Gestational Trophoblastic Disease AbdulkarimFarah
 
hmolesrd-190102152314.pptx
hmolesrd-190102152314.pptxhmolesrd-190102152314.pptx
hmolesrd-190102152314.pptxkajalgupta681731
 
Gestational trophoblastic disease ( Molar pregnancy )
Gestational trophoblastic disease ( Molar pregnancy )Gestational trophoblastic disease ( Molar pregnancy )
Gestational trophoblastic disease ( Molar pregnancy )Mohammed Barznji
 
Gestational trophoblastic neoplasia
Gestational trophoblastic neoplasiaGestational trophoblastic neoplasia
Gestational trophoblastic neoplasiarajeev sood
 
HYDATIDIFORM MOLE: APPROACH AND MANAGEMENT
HYDATIDIFORM MOLE: APPROACH AND MANAGEMENTHYDATIDIFORM MOLE: APPROACH AND MANAGEMENT
HYDATIDIFORM MOLE: APPROACH AND MANAGEMENTSharad Dahal
 

Similaire à Gestational trophoblastic disease 2 (20)

Seminar on gestational trophoblastic disease (gtd) (f inal)
Seminar on gestational trophoblastic disease (gtd) (f inal)Seminar on gestational trophoblastic disease (gtd) (f inal)
Seminar on gestational trophoblastic disease (gtd) (f inal)
 
Gestational trophoblastic disease (gtd.version gao)
Gestational trophoblastic disease (gtd.version gao)Gestational trophoblastic disease (gtd.version gao)
Gestational trophoblastic disease (gtd.version gao)
 
choriocarcinoma ppt.pptx
choriocarcinoma ppt.pptxchoriocarcinoma ppt.pptx
choriocarcinoma ppt.pptx
 
Hydatidiform mole
Hydatidiform moleHydatidiform mole
Hydatidiform mole
 
Gynecology 5th year, 5th & 6th lectures (Dr. Muhabat Salih Saeid)
Gynecology 5th year, 5th & 6th lectures (Dr. Muhabat Salih Saeid)Gynecology 5th year, 5th & 6th lectures (Dr. Muhabat Salih Saeid)
Gynecology 5th year, 5th & 6th lectures (Dr. Muhabat Salih Saeid)
 
Gestational Trophoblastic Disease - www.jinekolojivegebelik.com
Gestational Trophoblastic Disease - www.jinekolojivegebelik.comGestational Trophoblastic Disease - www.jinekolojivegebelik.com
Gestational Trophoblastic Disease - www.jinekolojivegebelik.com
 
Gestational Trophoblastic disease
Gestational Trophoblastic diseaseGestational Trophoblastic disease
Gestational Trophoblastic disease
 
Ectopic And Gtd
Ectopic And GtdEctopic And Gtd
Ectopic And Gtd
 
Gestational trophoblastic disease
Gestational trophoblastic diseaseGestational trophoblastic disease
Gestational trophoblastic disease
 
vesicular molle 1
vesicular molle 1vesicular molle 1
vesicular molle 1
 
GESTATIONAL TROPHOBLASTIC DISEASE...pptx
GESTATIONAL TROPHOBLASTIC DISEASE...pptxGESTATIONAL TROPHOBLASTIC DISEASE...pptx
GESTATIONAL TROPHOBLASTIC DISEASE...pptx
 
Gestational trophoblastic disease natangwe
Gestational trophoblastic disease natangweGestational trophoblastic disease natangwe
Gestational trophoblastic disease natangwe
 
Gestational Trophoblastic Disease -MBChB 6th Year 2018.pptx
Gestational Trophoblastic Disease -MBChB 6th Year 2018.pptxGestational Trophoblastic Disease -MBChB 6th Year 2018.pptx
Gestational Trophoblastic Disease -MBChB 6th Year 2018.pptx
 
Hydatidiform mole
Hydatidiform moleHydatidiform mole
Hydatidiform mole
 
Gestational Trophoblastic Disease.ppt
Gestational Trophoblastic Disease.pptGestational Trophoblastic Disease.ppt
Gestational Trophoblastic Disease.ppt
 
Gestational Trophoblastic Disease
 Gestational Trophoblastic Disease  Gestational Trophoblastic Disease
Gestational Trophoblastic Disease
 
hmolesrd-190102152314.pptx
hmolesrd-190102152314.pptxhmolesrd-190102152314.pptx
hmolesrd-190102152314.pptx
 
Gestational trophoblastic disease ( Molar pregnancy )
Gestational trophoblastic disease ( Molar pregnancy )Gestational trophoblastic disease ( Molar pregnancy )
Gestational trophoblastic disease ( Molar pregnancy )
 
Gestational trophoblastic neoplasia
Gestational trophoblastic neoplasiaGestational trophoblastic neoplasia
Gestational trophoblastic neoplasia
 
HYDATIDIFORM MOLE: APPROACH AND MANAGEMENT
HYDATIDIFORM MOLE: APPROACH AND MANAGEMENTHYDATIDIFORM MOLE: APPROACH AND MANAGEMENT
HYDATIDIFORM MOLE: APPROACH AND MANAGEMENT
 

Plus de student

Assessment examination
Assessment examinationAssessment examination
Assessment examinationstudent
 
Medications
MedicationsMedications
Medicationsstudent
 
Hysterosalpingography
HysterosalpingographyHysterosalpingography
Hysterosalpingographystudent
 
medicine.Poisoningintroduction.(dr.muhamad shaikhane)
medicine.Poisoningintroduction.(dr.muhamad shaikhane)medicine.Poisoningintroduction.(dr.muhamad shaikhane)
medicine.Poisoningintroduction.(dr.muhamad shaikhane)student
 
surgery.Congenital heart disease.(dr.aram)
surgery.Congenital heart disease.(dr.aram)surgery.Congenital heart disease.(dr.aram)
surgery.Congenital heart disease.(dr.aram)student
 
gynaecology.Ovarian tumours.(dr.salama)
gynaecology.Ovarian tumours.(dr.salama)gynaecology.Ovarian tumours.(dr.salama)
gynaecology.Ovarian tumours.(dr.salama)student
 
pediatrics.Wilson disease.(dr.bakr)
pediatrics.Wilson disease.(dr.bakr)pediatrics.Wilson disease.(dr.bakr)
pediatrics.Wilson disease.(dr.bakr)student
 
meidicine.Vasculitis 1.(dr.kawa)
meidicine.Vasculitis 1.(dr.kawa)meidicine.Vasculitis 1.(dr.kawa)
meidicine.Vasculitis 1.(dr.kawa)student
 
phthalmology.Refractive errors.(dr.ali)
phthalmology.Refractive errors.(dr.ali)phthalmology.Refractive errors.(dr.ali)
phthalmology.Refractive errors.(dr.ali)student
 
E.N.T.Dysphagia.(dr.hewa)
E.N.T.Dysphagia.(dr.hewa)E.N.T.Dysphagia.(dr.hewa)
E.N.T.Dysphagia.(dr.hewa)student
 
medicine.CRF.(dr.kawa)
medicine.CRF.(dr.kawa)medicine.CRF.(dr.kawa)
medicine.CRF.(dr.kawa)student
 
surgery.Cardiac surgery 1.(dr.aram)
surgery.Cardiac surgery 1.(dr.aram)surgery.Cardiac surgery 1.(dr.aram)
surgery.Cardiac surgery 1.(dr.aram)student
 
anasethesia.Cardiac arrest.(dr.amer)
anasethesia.Cardiac arrest.(dr.amer)anasethesia.Cardiac arrest.(dr.amer)
anasethesia.Cardiac arrest.(dr.amer)student
 
medicine.myeloma.(dr.anwar shexa)
medicine.myeloma.(dr.anwar shexa)medicine.myeloma.(dr.anwar shexa)
medicine.myeloma.(dr.anwar shexa)student
 

Plus de student (14)

Assessment examination
Assessment examinationAssessment examination
Assessment examination
 
Medications
MedicationsMedications
Medications
 
Hysterosalpingography
HysterosalpingographyHysterosalpingography
Hysterosalpingography
 
medicine.Poisoningintroduction.(dr.muhamad shaikhane)
medicine.Poisoningintroduction.(dr.muhamad shaikhane)medicine.Poisoningintroduction.(dr.muhamad shaikhane)
medicine.Poisoningintroduction.(dr.muhamad shaikhane)
 
surgery.Congenital heart disease.(dr.aram)
surgery.Congenital heart disease.(dr.aram)surgery.Congenital heart disease.(dr.aram)
surgery.Congenital heart disease.(dr.aram)
 
gynaecology.Ovarian tumours.(dr.salama)
gynaecology.Ovarian tumours.(dr.salama)gynaecology.Ovarian tumours.(dr.salama)
gynaecology.Ovarian tumours.(dr.salama)
 
pediatrics.Wilson disease.(dr.bakr)
pediatrics.Wilson disease.(dr.bakr)pediatrics.Wilson disease.(dr.bakr)
pediatrics.Wilson disease.(dr.bakr)
 
meidicine.Vasculitis 1.(dr.kawa)
meidicine.Vasculitis 1.(dr.kawa)meidicine.Vasculitis 1.(dr.kawa)
meidicine.Vasculitis 1.(dr.kawa)
 
phthalmology.Refractive errors.(dr.ali)
phthalmology.Refractive errors.(dr.ali)phthalmology.Refractive errors.(dr.ali)
phthalmology.Refractive errors.(dr.ali)
 
E.N.T.Dysphagia.(dr.hewa)
E.N.T.Dysphagia.(dr.hewa)E.N.T.Dysphagia.(dr.hewa)
E.N.T.Dysphagia.(dr.hewa)
 
medicine.CRF.(dr.kawa)
medicine.CRF.(dr.kawa)medicine.CRF.(dr.kawa)
medicine.CRF.(dr.kawa)
 
surgery.Cardiac surgery 1.(dr.aram)
surgery.Cardiac surgery 1.(dr.aram)surgery.Cardiac surgery 1.(dr.aram)
surgery.Cardiac surgery 1.(dr.aram)
 
anasethesia.Cardiac arrest.(dr.amer)
anasethesia.Cardiac arrest.(dr.amer)anasethesia.Cardiac arrest.(dr.amer)
anasethesia.Cardiac arrest.(dr.amer)
 
medicine.myeloma.(dr.anwar shexa)
medicine.myeloma.(dr.anwar shexa)medicine.myeloma.(dr.anwar shexa)
medicine.myeloma.(dr.anwar shexa)
 

Gestational trophoblastic disease 2

  • 1. Dr. Muhabat Salih Saeid MRCOG-London-UK
  • 2. Definition : It is a clinical term used to indicate three closely related conditions characterized by active abnormal proliferation of trophoblastic cells : : hydatidiform mole , invasive hydatidiform mole and Choriocarcinoma
  • 3.  These neoplasm's retain certain characteristic of the normal placenta such as invasive tendencies and the ability to make hCG hormone
  • 4.  Pathological classification :  Hydatidiform mole = 80 % of cases.  Invasive mole =12-15% of cases.  Choriocarcenoma=5-8% of cases.  Clinical classification : The course, and prognosis of the disease accurately reflected by hCG hormone  Benign = 80%  Malignant=20%
  • 5.  The hydatidiform mole incidence ranges from 1 in 522 pregnancies in Japan  To 1 in 1500 pregnancies in USA,and Sweden, this variation is not understood, but ethnic factors have been suggested .  The incidence is higher in the poorest socioeconomic classes than the semiprivate(4 times), and (8 times) than the privet , and these mostly related to diet especially protein deficiency .
  • 6.  The maternal age over 40 years found to have a 5.2-fold increased risk of trophoblastic disease in compression to the mothers below the age of 35 years.
  • 7.  Hydatidiform mole can be subdivided into: complete and partial mole
  • 8.  Based on: 1.Genetic and 2.Histopathological features
  • 9. Genetic features: One of the most remarkable discoveries about hydatidiform mole has been the demonstration that complete moles have chromosomes exclusively from the paternal side ,and the karyotype is nearly always 46,xx and only rarely is 46,XY observed.  The normal mechanism is for a haploid sperm,23X,to fertilize an empty egg, and to duplicate itself to form a 46,XX complement. Much less commonly ,two spermatozoa, one being 23,X, and the other,23,Y, can fertilize an empty egg, to give karyotype a 46,XY.
  • 10. •10
  • 11. Aretriploid in origin with two sets of paternal haploid genes and one set of maternal haploid genes
  • 12. •12
  • 13.  They occur, in almost all cases, following dispermic fertilization of an ovum.  There is usually evidence of a fetus or fetal red blood cells
  • 14. In the partial moles ,the normal finding is a triploid karyotype ,69 chromosomes instead of normal 46. The most common mechanism appears to be fertilization of normal egg by two sperm, giving a complement of 69,XXY.
  • 15. Complete mole :  there are numerous edematous vesicles, which looks like a bunch of small clear grapes,  usually no fetus, or membranes.,
  • 16. microscopically: there are:  large oedematous enlarged villi ,  a vascular ,  with variable degree of trophoblastic hyperplasia.  carries greater risk of malignancy and requires longer follow up than the partial mole.
  • 19. Partial mole:  Shows a less clear -cut picture ,with the formation of vesicles usually focal ,  fetus and membranes may present,  the vesicles have degree of vascularity.
  • 20.  In general ,the more active trophoblastic appearance the greater the risk of malignancy.  So the subsequent management depends more on the hCG results than the histological reports.
  • 21. Bleeding : Bleeding in early pregnancy after variable period of amenorrhea is the most common clinical sign of the mole (occurs in 90% of cases), with the passage of the vesicles.
  • 22. Hyperemesis gravidarum : Occurs into 25% of cases of moles ,and appears more common when the uterus is much enlarged and hCG levels are very high.
  • 23.  Uterine enlargement: The uterus is commonly “large for date”in 50% of case of moles ,  although, in a small proportion of cases the uterus corresponding to the gestational age or smaller than date.  The uterus having a doughy consistency.  The fetal parts are not palpable, and fetal heart is absent.
  • 24. Large theca lutein cysts of the ovary are present in “20%”of moles , these may be exaggerated the clinical picture of large for date uterus. These cysts are manifestation of excessive hCG.
  • 25. •25
  • 26. Pre-eclampsia :Occur in association with the moles with range widely from 12-54%,these due to differing times of diagnosis, the longer pregnancy progresses ,the greater chance to developing pre-eclampsia. If the signs of pre-eclampsia appears early in pregnancy , the possibility of hydatidiform mole should be looked for with out delay.
  • 27.  Hyperthyrodism: Develop in small proportion of women ,and this may be due to thyrotrophic effects of the human chorionic thyrotrophin , which may lead to goitre,fine tremor ,supra-ventricular tachycardia, and weight loss.  DIC can develop in long-standing hydatidiform moles , when there is embolization of trophoblastic tissue to the lung, leads to thromboplastic substances which stimulate fibrin,and platelet deposition.
  • 28. History and examination : From the history of amenorrhea ,passage of vesicles vaginally with bleeding ;the size and consistency of the uterus.
  • 29. The increasing use of ultrasound in early pregnancy has probably led to the earlier diagnosis of molar pregnancy
  • 30. By the U/S examination can be diagnosed from very early pregnancy ,characterized by “Snow-storm" appearance.
  • 31. •31
  • 32. By very high levels of serum hCG than the normal singleton pregnancy ,which is diagnostic and prognostic to the course of the disease ,with very short dappling time.
  • 33. The risks of hydatidiform mole are:  Immediate hemorrhage ,sepsis, or pre- eclampsia; the treatment of these conditions has vastly improved recently.  Molar metastases : Of a non proliferative ”benign” type can occur.
  • 34. Choriocarcinoma: The most important danger association with the hydatidiform mole is the development of malignant GTD(Invasive mole or choriocarcinoma) in about 10% of cases,
  • 35. The aim of treatment is to eliminate all trophoblastic tissue from the maternal systems ; If the hydatidiform mole diagnosed ,steps should be taken to evacuate the uterus, and this achieved by:
  • 36. Suction & curettage (S&C): The method of choice even when evacuation large mole
  • 37. Under GA.  Cervix dilation till 12mm.and S&C induced to the uterine cavity.  I.V oxytocin infusion is started .  S&C started by negative pressure of about 60 to 70cmHg.  The curette is genteelly rotated to ovoid perforation of the soft uterus, and the majority of the molar tissue is evacuated rapidly ,and the uterine size decreases
  • 38. Uterine stimulation.
  • 39. Medical termination of complete molar pregnancies including cervical preparation prior to suction evacuation, should be avoided where possible.
  • 40.  The contraction of the myometrium may force tissue into the venous spaces at the site of the placental bed.  The dissemination of this tissue may lead to the profound deterioration in the woman, with embolic and metastases disease occurring in the lung
  • 41. Surgical evacuation:
  • 42. Surgical evacuation: Hysterectomy has been recommended as a suitable method of treating hydatidiform mole in older women who completed their family ,to reduce the risk of post-molar trophoblastic disease . .The hysterectomy should be carried out with little monopolization to ovoid precipitating mobilization of trophoblastic tissue.
  • 43.  Inpartial molar pregnancies where the size of the fetal parts deters the use of suction curettage, medical termination can be used.
  • 44. After the uterus has been evacuated :  About 90% of cases ,the trophoblastic tissue die out completely.  About 10% of cases the trophoblastic tissue does not die out completely and may persist or recur as : invasive mole or choriocarcinoma.
  • 45. So it is important that women who have had a hydatidiform mole:  should have close follow-up by serum hCG levels after the evacuation of the uterus, To ensure early recognition of persistent trophoblastic tissue .
  • 46.  After a molar pregnancy ,the hCG levels will usually have returned to non pregnant levels by 4 to 6 weeks after evacuation.  The follow-up is recommended for 2 years in cases of complete moles, and 6 months of cases of partial moles after the evacuation of uterus.
  • 47.  Serial quantitative measurement of serum hCG level at weekly intervals, after evacuation of moles till 4 to 5 weeks when the hCG become normal. Then every other week .When the titer gets negative the measurements are done every month fore 1 year.
  • 48.  Indicationof chemotherapy after the evacuation of the hydatidiform mole in: Serum hCG >20000 i.u/L , at any time after evacuation of mole.  Raised hCG at 4 to 6 weeks after evacuation of mole.
  • 49. Evidence of metastases ,hepatic,brain,and pulmonary. Persistent uterine hemorrhage after evacuation of mole with raised hCG levels.
  • 50. To achieve effective follow-up ,the pregnancy is better to be avoided ,and also the use of oral contraceptive pills until the hCG levels returns to normal after the evacuation of the mole.  Early diagnosis of persistent trophoblastic disease ensures a good prognosis and an effective system of follow-up.
  • 51. Malignant trophoblastic disease can exist in two forms: Invasive mole = non-metastatic form. Choriocarcinoma = metastatic form .
  • 52.  Both treated with the chemotherapy and monitored by hCG tumor marker.  Choriocarcinoma subdivide into :  good-prognosis (Low-risk) ,and  poor- prognosis (High-risk).
  • 53.  The diagnosis of invasive moles or “chorioadenoma destruens” is applied to the moles characterized by :  Abnormal peneterativeness and,  Extensive local invasion, along with  Excessive trophoblastic proliferation ,  With preserved villous pattern.
  • 54. The proliferative villi may invade the myomatrum ,paramatrum or the vaginal wall, although there is rarely evidence of metastasis.  The morbidity and mortality of this disease results from the penetration of the tumar through the myomatrum and to the pelvic vessels with the resultant hemorrhage “the morbidity and mortality rate 10 %” .
  • 55.  Choriocarcinoma subdivide into: good-prognosis (low risk). Poor- Prognosis (High risk).
  • 56. •56
  • 57.  The incidence of choriocarcinoma in the West: 1 :10000 and 1:70000 pregnancies; and  In Asia between 1:250 and 1:6000 pregnancies..
  • 58.  The antecedent pregnancy is : Hydatidiform mole in about 57% of cases. Normal pregnancy in about 26% of cases. Abortion and ectopic pregnancy in about 17% of cases.
  • 59.  The risk of Choriocarcinoma after a hydatidiform mole is about 2-4% which is 1000 times greater than after a normal pregnancy.
  • 60.  Choriocarcinoma is more likely to occur after complete mole .  The incidence is in excess in maternal blood group A, and deficit in group O.
  • 61.  Site: In the uterus 90% of cases; 10 % of cases in the ovaries ,vagina, vulva, lung, liver, and brain.
  • 62.  Macroscopically:  Uterus: It may be localized in the form of hemorrhagic polyp or multiple hemorrhagic ,necrotic masses in the cavity.  Some times it is present in the uterine wall (intramural) and the cavity is empty.
  • 63. Ovaries : May show stormal lutein hyperplasia, and theca-lutein cysts. And may be site of secondaries.
  • 64.  Microscopically:  Malignant hyperplasia of both cytotrophoblasts,and syncytiotrophoblasts.  Extensive hemorrhage.  Absence of villi.  Destruction of the surrounding myomatrum.
  • 65. Direct : Through the myomatrum and may end in uterine perforation ,internal hemorrhage, and peritonitis .Through the fallopian tubes to the ovaries.
  • 66. •66
  • 67.  Blood : The main method of spread ,and occurs to;  Genital : Vagina, vulva, and ovary.  Extra genital : Lung, liver, brain, and bones especially skull and spine.  The lung is the commonest site for secondaries and haemoptysis may be the presenting symptom.
  • 68.  Lung  Vagina  Brain  Liver •68
  • 69.  Vaginal bleeding.  Haemoptysis.  Intraperitoneal hemorrhage.  Peritonitis.  Metastasis to the vital organs e.g,brain.  Pulmonary complications.
  • 70.  Symptoms :  Recent history of expulsion of vesicular mole ,or abortion, or full term pregnancy.  Persistent vaginal bleeding is the commonest presentation.  Haemoptysis.  Abdominal swelling (uterus or ovaries).
  • 71.  PersistentGTD should be considered in any woman developing: acute respiratory or neurological symptoms after any pregnancy.
  • 72.  Signs:  Marked deterioration of the general condition.  An abdominal swelling may be felt.
  • 73.  Vaginally : The uterus symmetrically enlarged (less than 12 weeks). The ovaries may be enlarged. Hemorrhagic secondaries may be seen in the vagina or vulva
  • 74.  Investigation:  Serum hCG.  Chest X-ray for pulmonary metastasis.  L.F.T .  Liver scan.  CAT scan for the secondaries.  EEG .  U/S for abdomen and pelvis.  Diagnostic D&C.
  • 75. The clinical classification of gestational trophoblastic disease: I. Non-metastatic. II. Metastatic: A. Low risk: All patient of documented metastatic disease who do not have “high- risk factors”.
  • 76. B. High risk: 1. B-hCG level higher than 100.000miu/ml. 2. Associated pregnancy episode more than 4 months before the diagnosis.
  • 77. 3. Following full-term pregnancy. 4. Liver or brain metastasis. 5. Failure of previous chemotherapy. 6. Symptoms of malignancy more than 4 months
  • 78. Prophylaxis: After care of vesicular mole;  D&C after one week of the evacuation.  Monitored for the signs and symptoms of trophoblastic neoplassmic by:. I. serial hCG.
  • 79. II. Diagnostic D&C is done if :  The hCG levels remains high.  The hCG levels rises after gets negative.  Uterine sub involution.  Persistence of theca lutein cysts in the ovaries.  Every case of secondary postpartum haemorrhage.  Every case of post abortive bleeding.
  • 80. I. Non metastatic GTD: o Methotrexate (antimetabolite) +folinic acid. o The cytotoxic therapy is controlled by doing CBC,platelet count and LFT. o After the the hCG level gets normal ;stop the therapy and follow-up by weekly estimation of hCG levels.
  • 81. Women scoring: Non metastatic GTD,and(low risk) GTD receive intramuscular methotrexate on alternate days, followed by six rest days, with each course consisting of four injections
  • 82. o Physical examination, chest x- ray, and LFT. o Total abdominal hysterectomy ,if the patient does not desire to maintain child-bearing, in the middle of the first treatment course .
  • 83. II. Low metastatic GTD: o Methotraxate , or Actinomycin D ,if there is resistance ,change to triple chemotherapy.
  • 84. o The criteria for initiation, and continuation of each methotraxate treatment ;  Platelet count more than 100.000.  WBC more than 3000.  Absolute neutrophil count between 1000- 1500.  Normal LFT, renal function.
  • 85. III. High risk metastatic GTD : o Triple chemotherapy : Methotraxate, Actinomycin D, and Cytoxan.
  • 86. o Surgery:  TAH may be done in patients not desirous of further reproduction.  Surgical extirpation of isolated metastasis e.g. pulmonary if resistant to chemotherapy.
  • 87. o Irradiation: Whole brain irradiation for cerebral metastases , The whole organ irradiation for hepatic metastases
  • 88.  After successful therapy ,the hCG levels are obtained :  every 2weeks for 3 months,  every month for 3months,  every 2months for 6 months then every sixes months indefinitely.
  • 89.  If at any time hCG levels rises, repeat the evaluation , staging ,and chemotherapy.  Physical examination, and chest x-ray follow-up at 6 weeks, then every 3months for one year, then every 6 months for one year.
  • 90.  Pregnancy is not allowed except after one year of negative follow up but with danger of :  Molar pregnancy (4-5 times greater risk).  Spontaneous abortion.  Premature delivery.
  • 91. If a further molar pregnancy does occur, in 68–80% of cases it will be of the same histological type
  • 92.  Women who undergo chemotherapy are advised not to concieve for one year after completion of treatment
  • 93. THIS IS THE END OF THE LECTURE . HOPE YOU ENJOYED IT ! THANK YOU ! ! !